Krilogy Financial LLC Reduces Position in Zoetis Inc. $ZTS

Krilogy Financial LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 88.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,256 shares of the company’s stock after selling 24,280 shares during the quarter. Krilogy Financial LLC’s holdings in Zoetis were worth $403,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the period. Nordea Investment Management AB lifted its stake in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the period. Seilern Investment Management Ltd lifted its stake in Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the period. Assenagon Asset Management S.A. lifted its stake in Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its stake in Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after acquiring an additional 18,040 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $116.01 on Friday. The stock has a fifty day simple moving average of $121.02 and a two-hundred day simple moving average of $125.73. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The company has a market cap of $48.80 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $152.25.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.